Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02170012 · ClinicalTrials.gov registry record · Phase 1
A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02170012 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT02170012, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study in healthy elderly people is to evaluate safety, toleration and time course of plasma concentration of multiple oral doses of PF-06743649- The pharmacodynamic activity of PF-06743649 will also be assessed.
Interventions
- DRUG Placebo
- DRUG PF-06743649
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02170012
The ClinicalTrials.gov registry entry for NCT02170012 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02170012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02170012 about?
NCT02170012 is a clinical study titled "A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649". The purpose of this study in healthy elderly people is to evaluate safety, toleration and time course of plasma concentration of multiple oral doses of PF-06743649- The pharmacodynamic activity of PF-06743649 will also be assessed.
What is the current status of trial NCT02170012?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-07. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02170012?
The interventions under investigation include: Placebo (DRUG), PF-06743649 (DRUG).
Who is sponsoring clinical trial NCT02170012?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.